Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Federal Reserve presses ahead with quarter-point rate rise despite banking turmoil
    • Rahul Gandhi sentenced to two years in prison over Modi remarks
    • ‘Close to thin ice’: looming credit crunch puts pressure on Fed
    • Emmanuel Macron holds firm on pensions reform amid protests
    • ‘Master of clocks’: can Macron wait out a crisis of his own making?
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Banks in turmoil
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Swiss regulator defends $17bn wipeout of AT1 bonds in Credit Suisse deal
      • US bondholders prepare to sue Swiss government over $17bn Credit Suisse wipeout
      • What the takeover of Credit Suisse means for UBS
      • British billionaire Jim Ratcliffe plans to offer more than £5bn for Manchester United
      • Bank shares slide as Janet Yellen plays down ‘blanket’ deposit guarantee
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Swiss regulator defends $17bn wipeout of AT1 bonds in Credit Suisse deal
      • US bondholders prepare to sue Swiss government over $17bn Credit Suisse wipeout
      • Live news: UK parliament bans TikTok from devices
      • Live news updates from March 22: Fed raises rates 25 bps, UK inflation hits 10.4%
      • Bank shares slide as Janet Yellen plays down ‘blanket’ deposit guarantee
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
      Most Read
      • A hefty shock awaits those who see little difference between Starmer and Sunak
      • It’s unwise to get Trump on a technicality
      • Beware the ‘sensible’ crypto crowd — they’re worse than the fanatics
      • Risk of ‘industrial capture’ looms over AI revolution
      • EY, KPMG and the fallout of two accounting scandals
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • From SVB to the BBC: why did no one see the crisis coming?
      • Football’s first female super-agent Rafaela Pimenta on dealmaking and discrimination
      • Social media content moderators lead charge for better rights
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • Everything I, an Italian, thought I knew about Italian food is wrong
      • We should regulate SUVs out of existence
      • The bleak beauty of Death Valley
      • Succession Season 4 puts the Roys on the brink of battle royal — review
      • Bring on the near-misses to avoid the financial meltdowns
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Illumina Inc

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Friday, 17 March, 2023
      InterviewCarl Icahn
      Carl Icahn urges Fed to keep fighting inflation ‘disease’

      Comments by activist investor come ahead of US central bank’s rate-setting meeting next week

    • Monday, 13 March, 2023
      Carl Icahn takes aim at genome sequencer Illumina over Grail deal

      Company’s shares jump after activist investor launches proxy battle

    • Tuesday, 7 February, 2023
      Health sector
      Illumina boosts spending on US lobbying amid opposition to Grail acquisition

      Genome sequencing company paid firms $14.6mn over past two years to try to sway lawmakers

    • Sunday, 29 January, 2023
      News in-depth
      Has Illumina taken the wrong path in its Grail quest?

      DNA sequencing expert’s investors question acquisition of cancer testing group that has also angered EU regulators

    • Monday, 5 September, 2022
      Illumina to challenge Brussels over any block on Grail merger

      US biotech to object to impending EU ruling on $8bn deal for cancer screening group

    • Thursday, 1 September, 2022
      Illumina wins battle against US regulators trying to block $8bn Grail deal

      Setback for FTC after administrative law judge gives nod to acquisition of cancer testing group

    • Wednesday, 13 July, 2022
      EU business regulation
      EU court ruling expands Brussels’ powers to scrutinise tech mergers

      Ruling allows European probe of Illumina’s $8bn Grail takeover and sets precedent for deeper oversight of deals

    • Sunday, 16 January, 2022
      Illumina says EU probe of $8bn Grail deal could hit biotech investment

      Chief executive deSouza attacks regulatory intervention over cancer test company

    • Wednesday, 18 August, 2021
      Illumina pushes ahead with closing $8bn Grail merger in defiance of EU probe

      US biotech takes aggressive step over cancer-screening deal fearing Brussels review will not beat deadline

    • Wednesday, 14 July, 2021
      Brooke Masters
      Competition enforcement is harder than it looks

      Novel antitrust cases complicate efforts to tackle climate change and healthcare

    • Tuesday, 1 June, 2021
      Illumina accuses US regulators of time-wasting over $8bn Grail deal

      Biotech group’s chief warns lives will be at risk if approval process is delayed

    • Thursday, 29 April, 2021
      Illumina sues Brussels over probe into $8bn cancer deal for Grail

      US genomics company takes rare step after authorities indicate they will review the deal

    • Wednesday, 31 March, 2021
      Lex
      Illumina: vertical acquisition in the crosshairs Premium content

      Competition regulator’s move on Grail purchase confirms era of bolder antitrust bodies

    • Tuesday, 23 February, 2021
      Genomics
      Genomic sequencing head calls for ‘Bio Force’ to detect virus threats

      Illumina’s Francis De Souza says global co-operation needed to keep up with new strains

    • Monday, 21 September, 2020
      Biotech
      Illumina agrees $8bn deal for cancer screening group Grail

      Genetic sequencing company set to take full ownership of start-up

    • Friday, 3 January, 2020
      Pharmaceuticals sector
      Illumina and Pacific Biosciences call off merger

      Mooted $1.2bn deal halted after scrutiny by UK and US competition watchdogs

    • Monday, 30 July, 2018
      Technology sector
      Illumina shares lit up by earnings beat, outlook raise
    • Tuesday, 1 August, 2017
      Corporate earnings and results
      Illumina rises as its boosts forecast, posts earnings beat
    • Thursday, 10 November, 2016
      LexEuropean companies
      Siemens: healthy cynicism

      Separating the healthcare unit makes sense. Announcing it now does not

    • Tuesday, 11 October, 2016
      World
      Healthcare clocks sharpest decline in broad S&P 500 sell-off
    • Tuesday, 11 October, 2016
      US equities
      Illumina shares slide on sales ‘credibility gap’

      US stocks retreat as healthcare sector posts heaviest losses

    • Tuesday, 11 October, 2016
      US equities
      S&P falls 1% as US stocks extend declines
    • Monday, 10 October, 2016
      Companies
      Illumina tumbles 25% after sales warning
    • Thursday, 2 June, 2016
      Pharmaceuticals sector
      President raises patient and business hope for cancer treatment

      Many experts believe a new type of drug promises to revolutionise treatment

    • Friday, 1 April, 2016
      Pharmaceuticals sector
      Whole-genome breakthrough promises tonic for healthcare

      Accurately sequencing an individual’s DNA for less than $1,000 is now possible

    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition

    Top sections

    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Banks in turmoil
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports

    FT recommends

    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • FTfm
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In